237.26
price down icon0.04%   -0.17
 
loading
Schlusskurs vom Vortag:
$237.43
Offen:
$236.37
24-Stunden-Volumen:
215.95K
Relative Volume:
0.27
Marktkapitalisierung:
$34.88B
Einnahmen:
$4.93B
Nettoeinkommen (Verlust:
$1.25B
KGV:
28.01
EPS:
8.47
Netto-Cashflow:
$1.38B
1W Leistung:
-2.16%
1M Leistung:
+1.51%
6M Leistung:
+10.57%
1J Leistung:
+30.04%
1-Tages-Spanne:
Value
$233.47
$237.44
1-Wochen-Bereich:
Value
$233.47
$243.41
52-Wochen-Spanne:
Value
$170.56
$263.05

Resmed Inc Stock (RMD) Company Profile

Name
Firmenname
Resmed Inc
Name
Telefon
(858) 746-2400
Name
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Name
Mitarbeiter
10,140
Name
Twitter
@resmed
Name
Nächster Verdiensttermin
2024-10-24
Name
Neueste SEC-Einreichungen
Name
RMD's Discussions on Twitter

Vergleichen Sie RMD mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Medical Instruments & Supplies icon
RMD
Resmed Inc
237.37 34.88B 4.93B 1.25B 1.38B 8.47
Medical Instruments & Supplies icon
ISRG
Intuitive Surgical Inc
590.72 211.02B 8.35B 2.32B 1.30B 6.41
Medical Instruments & Supplies icon
BDX
Becton Dickinson Co
227.87 65.90B 20.64B 1.73B 2.94B 6.02
Medical Instruments & Supplies icon
ALC
Alcon Inc
88.65 44.42B 9.76B 1.16B 665.00M 2.34
Medical Instruments & Supplies icon
WST
West Pharmaceutical Services Inc
318.69 23.39B 2.88B 499.60M 321.60M 6.74

Resmed Inc Stock (RMD) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-01-16 Eingeleitet Goldman Buy
2025-01-10 Eingeleitet Piper Sandler Neutral
2024-12-13 Eingeleitet Stifel Hold
2024-09-24 Eingeleitet Robert W. Baird Outperform
2024-09-18 Herabstufung Wolfe Research Peer Perform → Underperform
2024-09-04 Herabstufung Needham Buy → Hold
2024-06-25 Herabstufung Oppenheimer Outperform → Perform
2024-06-24 Herabstufung Citigroup Buy → Neutral
2024-02-06 Fortgesetzt KeyBanc Capital Markets Overweight
2023-10-27 Hochstufung Morgan Stanley Equal-Weight → Overweight
2023-10-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2023-10-09 Hochstufung JP Morgan Neutral → Overweight
2023-09-29 Herabstufung Wolfe Research Outperform → Peer Perform
2023-09-06 Hochstufung Needham Hold → Buy
2023-09-05 Herabstufung UBS Buy → Neutral
2023-08-01 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2023-05-23 Eingeleitet UBS Buy
2023-04-14 Eingeleitet Mizuho Buy
2023-01-17 Hochstufung JP Morgan Neutral → Overweight
2022-10-28 Herabstufung Citigroup Buy → Neutral
2022-10-20 Hochstufung BofA Securities Neutral → Buy
2022-10-12 Eingeleitet Jefferies Hold
2022-09-08 Hochstufung Citigroup Neutral → Buy
2022-08-15 Herabstufung CLSA Buy → Outperform
2022-08-12 Herabstufung Citigroup Buy → Neutral
2022-08-12 Herabstufung JP Morgan Overweight → Neutral
2022-08-12 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2022-06-06 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2022-04-06 Eingeleitet Wolfe Research Outperform
2022-01-31 Hochstufung Citigroup Neutral → Buy
2022-01-31 Hochstufung Goldman Neutral → Buy
2022-01-28 Hochstufung RBC Capital Mkts Underperform → Sector Perform
2022-01-24 Hochstufung BofA Securities Underperform → Neutral
2022-01-24 Hochstufung JP Morgan Neutral → Overweight
2022-01-13 Hochstufung CLSA Outperform → Buy
2022-01-13 Hochstufung Robert W. Baird Neutral → Outperform
2021-12-21 Hochstufung KeyBanc Capital Markets Sector Weight → Overweight
2021-12-06 Hochstufung Macquarie Neutral → Outperform
2021-10-22 Hochstufung CLSA Underperform → Outperform
2021-08-02 Herabstufung CLSA Outperform → Sell
2021-08-02 Herabstufung Needham Buy → Hold
2021-07-28 Hochstufung Jefferies Underperform → Hold
2021-07-26 Herabstufung JP Morgan Overweight → Neutral
2021-07-14 Eingeleitet RBC Capital Mkts Underperform
2021-06-28 Herabstufung Citigroup Buy → Neutral
2021-06-22 Hochstufung Macquarie Neutral → Outperform
2021-06-22 Eingeleitet Robert W. Baird Neutral
2021-06-21 Bestätigt Needham Buy
2021-06-16 Herabstufung BofA Securities Neutral → Underperform
2021-06-09 Hochstufung CLSA Sell → Outperform
2021-05-21 Hochstufung JP Morgan Neutral → Overweight
2021-05-11 Hochstufung Citigroup Neutral → Buy
2021-04-30 Herabstufung Citigroup Buy → Neutral
2021-03-16 Hochstufung Needham Hold → Buy
2020-11-02 Hochstufung UBS Neutral → Buy
2020-10-30 Hochstufung JP Morgan Underweight → Neutral
2020-10-27 Hochstufung BofA Securities Underperform → Neutral
2020-08-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-06-17 Hochstufung Morgan Stanley Equal-Weight → Overweight
2020-05-01 Herabstufung JP Morgan Neutral → Underweight
2020-05-01 Hochstufung Oppenheimer Perform → Outperform
2020-02-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-02-03 Eingeleitet CLSA Underperform
2020-01-31 Herabstufung UBS Buy → Neutral
2020-01-10 Eingeleitet Oppenheimer Perform
2019-11-22 Eingeleitet KeyBanc Capital Markets Sector Weight
2019-07-29 Hochstufung UBS Neutral → Buy
2019-07-16 Herabstufung UBS Buy → Neutral
2019-05-06 Hochstufung UBS Neutral → Buy
2019-04-18 Hochstufung JP Morgan Underweight → Neutral
2019-01-25 Herabstufung Goldman Buy → Neutral
2019-01-25 Herabstufung JP Morgan Neutral → Underweight
2018-10-26 Hochstufung Credit Suisse Neutral → Outperform
2018-07-02 Eingeleitet Goldman Buy
Alle ansehen

Resmed Inc Aktie (RMD) Neueste Nachrichten

pulisher
04:59 AM

Kestra Private Wealth Services LLC Increases Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat

04:59 AM
pulisher
Feb 11, 2025

ResMed CFO Executes Planned Stock Transaction - TipRanks

Feb 11, 2025
pulisher
Feb 11, 2025

ResMed Getting Closer To Key Technical Benchmark - MSN

Feb 11, 2025
pulisher
Feb 11, 2025

ResMed Close To Joining Very Elite Stock Group - Investor's Business Daily

Feb 11, 2025
pulisher
Feb 11, 2025

Stephens Inc. AR Decreases Stock Position in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 11, 2025
pulisher
Feb 11, 2025

Ex-Dividend Reminder: TJX Companies, UNITIL and ResMed - Nasdaq

Feb 11, 2025
pulisher
Feb 11, 2025

Down 4%, is the ResMed share price in the buy zone? - MSN

Feb 11, 2025
pulisher
Feb 10, 2025

Research Analysts Issue Forecasts for ResMed Q3 Earnings - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Resmed Chief Financial Officer Sells 1,000 Shares -February 10, 2025 at 06:33 pm EST - Marketscreener.com

Feb 10, 2025
pulisher
Feb 10, 2025

Revisiting ResMed In 2025: Strong Q2 Financial Results And The Growing Demand For Sleep Apnea Solutions - Seeking Alpha

Feb 10, 2025
pulisher
Feb 10, 2025

Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance Australia

Feb 10, 2025
pulisher
Feb 10, 2025

Insider Selling: ResMed Inc. (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Sumitomo Mitsui Trust Group Inc. Trims Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

ResMed Inc. (NYSE:RMD) Stock Position Lifted by Mirae Asset Global Investments Co. Ltd. - MarketBeat

Feb 10, 2025
pulisher
Feb 09, 2025

ResMed Inc Announces Proposed Sale of Securities by Officer - TipRanks

Feb 09, 2025
pulisher
Feb 09, 2025

Tobam Lowers Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

With 69% ownership, ResMed Inc. (NYSE:RMD) boasts of strong institutional backing - Yahoo Finance

Feb 09, 2025
pulisher
Feb 09, 2025

Stephens Investment Management Group LLC Decreases Position in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

State of Alaska Department of Revenue Lowers Position in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 09, 2025
pulisher
Feb 09, 2025

Capital Investment Services of America Inc. Sells 1,961 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 09, 2025
pulisher
Feb 08, 2025

What is William Blair's Estimate for ResMed FY2025 Earnings? - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

1,438 Shares in ResMed Inc. (NYSE:RMD) Acquired by Chicago Partners Investment Group LLC - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Jericho Financial LLP Makes New Investment in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

abrdn plc Lowers Stock Holdings in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 08, 2025
pulisher
Feb 07, 2025

William Blair Weighs in on ResMed’s Q3 Earnings (NYSE:RMD) - Defense World

Feb 07, 2025
pulisher
Feb 06, 2025

ResMed (NYSE:RMD) Shares Gap Up on Analyst Upgrade - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

ResMed Inc. (NYSE:RMD) Stock Holdings Increased by Spire Wealth Management - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

ResMed Inc. (NYSE:RMD) Stock Position Lowered by Oak Family Advisors LLC - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Chicago Capital LLC Purchases 3,551 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

ResMed Inc Director Plans Sale of 2,000 Shares - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Cibc World Market Inc. Grows Stake in ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

ResMed Inc. Reports Changes in CDI and Security Issuances - MSN

Feb 06, 2025
pulisher
Feb 05, 2025

Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus.com

Feb 05, 2025
pulisher
Feb 05, 2025

Looking to bag the record high ResMed dividend? You better hurry! - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

ResMed Inc. Announces Changes in Beneficial Ownership - TipRanks

Feb 05, 2025
pulisher
Feb 05, 2025

ResMed (NYSE:RMD) Given New $280.00 Price Target at KeyCorp - MarketBeat

Feb 05, 2025
pulisher
Feb 05, 2025

ResMed (NYSE:RMD) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat

Feb 05, 2025
pulisher
Feb 04, 2025

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

ResMed: Digital Health Drives Q2 Growth - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

BDF Gestion Sells 1,532 Shares of ResMed Inc. (NYSE:RMD) - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Resmed Incorporated's Fiscal 2Q Revenue, NPAT Results Above Consensus; Jarden Research Says - Marketscreener.com

Feb 04, 2025
pulisher
Feb 04, 2025

Zacks Research Issues Optimistic Outlook for ResMed Earnings - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

ResMed Inc. (NYSE:RMD) Declares $0.53 Quarterly Dividend - MarketBeat

Feb 04, 2025

Finanzdaten der Resmed Inc-Aktie (RMD)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
medical_instruments_supplies ALC
$88.65
price down icon 1.35%
medical_instruments_supplies WST
$318.69
price down icon 1.06%
medical_instruments_supplies COO
$91.88
price down icon 1.74%
$206.14
price down icon 2.02%
medical_instruments_supplies BAX
$30.29
price down icon 1.20%
Kapitalisierung:     |  Volumen (24h):